Article Text

PDF
The Janus face of BNP therapy in chronic heart failure: beneficial effects unmasked by β blockers?
  1. Matthias Dewenter1,
  2. Christiane Vettel1,
  3. Ali El-Armouche1,2
  1. 1Institute of Pharmacology, University Medical School Göttingen, Göttingen, Germany
  2. 2Department of Pharmacology, Faculty of Medicine, University of Technology-Dresden, Dresden, Germany
  1. Correspondence to Professor Ali El-Armouche, Institute of Pharmacology, University Medical School Göttingen, Robert-Kochstr. 40, 37075 Göttingen, Germany; ali.el-armouche{at}med.uni-goettingen.de

Statistics from Altmetric.com

Heart failure is among the most common causes of morbidity and mortality worldwide and almost half of the patients die from sudden cardiac death, most likely due to ventricular tachyarrhythmias. The current therapeutic strategies for heart failure and arrhythmias are complex and only moderately efficient. In the last decades successful therapies were mainly based on the neurohormonal blockade, including β blockers, ACE inhibitors, angiotensin II receptor AT1 blockers and aldosterone antagonists. However, the lack of benefit of α1-adrenoceptor antagonists, endothelin receptor antagonists and α2-adrenoceptor agonists indicate that the principle of ‘straightforward’ neurohumoural blockade is limited and new strategies are yet to be identified.1 One particular new approach may focus on deciphering the complex interplay between the classical neurohormonal pathways and diverse biologically active peptides during heart failure progression. Indeed, the profile of atrial natriuretic peptide and brain natriuretic peptide (BNP) might offer a new and intriguing target. In particular BNP, which is primarily secreted from the cardiac ventricle upon volume and pressure overload, is a well-established and critical biomarker for risk stratification in heart failure and has various haemodynamic effects such as enhanced natriuresis, vasorelaxation, inhibition of renin-angiotensin system (RAS) and ameliorating cardiac fibrosis (see figure 1).2 The apparent beneficial effects of BNP in opposing RAS overdrive and therefore potentially cardiac remodelling seem to be ideally suited for the development of an effective, rational therapeutic approach.

Figure 1

Schematic figure illustrating the brain natriuretic peptide (BNP)-dependent pathways and the possible interactions with β blocker treatment. cGMP, cyclic guanosine monophosphate, cAMP, cyclic adenosine monophosphate, NPR, natriuretic peptide receptor. For details see main text.

The first clinical studies conducted in the 1990s showed …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles